{"id":40331,"date":"2025-09-03T07:10:15","date_gmt":"2025-09-03T07:10:15","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/40331\/"},"modified":"2025-09-03T07:10:15","modified_gmt":"2025-09-03T07:10:15","slug":"koreas-neurophet-inrad-to-establish-global-standards-for-alzheimers-disease-and-dementia-data","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/40331\/","title":{"rendered":"Korea&#8217;s Neurophet &#038; InRAD to establish global standards for Alzheimer&#8217;s disease and dementia data"},"content":{"rendered":"<p>\t\t\t\t\t\tKorea&#8217;s Neurophet &amp; InRAD to establish global standards for Alzheimer&#8217;s disease and dementia data<\/p>\n<p class=\"float-left\">September 3, 2025 | Wednesday | News<\/p>\n<p>\t\t\t\t\t\t\tNeurophet&#8217;s AI-based brain imaging analysis solutions to support global standardisation of Alzheimer&#8217;s and other dementia-related data<\/p>\n<p>\t\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2025\/09\/dem-26584.jpg\" class=\"img-fluid w-100 pl-5 pr-5\" alt=\"image credit- shutterstock\"\/><\/p>\n<p class=\"mt-3 text-center\">image credit- shutterstock<\/p>\n<p style=\"text-align: justify;\">Neurophet, a South Korea-based artificial intelligence (AI) solution startup for brain disorders diagnosis and treatment has signed a Memorandum of Understanding (MoU) with the International Registry for Alzheimer&#8217;s Disease and Other Dementias Foundation (InRAD) to accelerate global standardisation of Alzheimer&#8217;s and dementia-related data.<\/p>\n<p style=\"text-align: justify;\">Through this agreement,\u00a0Neurophet and InRAD aim to strengthen their collaboration to help establish globally harmonized standards for Alzheimer&#8217;s disease and other dementias real-world data. The partnership also seeks to enable the seamless integration of AI-based neuroimaging technologies into the broader real-world data landscape, removing one of the key practical barriers to evidence generation &#8211; namely, the lack of coordinated approaches &#8211; while acknowledging the wider adoption of these technologies in everyday clinical practice.<\/p>\n<p style=\"text-align: justify;\">The partnership will focus on key initiatives including:<\/p>\n<ul style=\"text-align: justify;\" type=\"disc\">&#13;<\/p>\n<li>Enhancing clinical workflows involving MRI and PET analysis<\/li>\n<p>&#13;<\/p>\n<li>Collecting and aggregating clinical imaging and quantitative data<\/li>\n<p>&#13;<\/p>\n<li>Validating clinical utility of AI-based analysis solutions<\/li>\n<p>&#13;<\/p>\n<li>Developing joint research and education programmes<\/li>\n<p>&#13;\n<\/ul>\n<p style=\"text-align: justify;\">Neurophet&#8217;s flagship products \u2014 Neurophet AQUA AD, an Alzheimer&#8217;s Disease Treatment Prescription\/Treatment Effect and Side Effect Monitoring Software; and Neurophet SCALE PET, a PET Image Quantitative Analysis Software; and Neurophet AQUA, a Brain MRI Analysis Software \u2014 will be available for utilization in this collaboration.<\/p>\n<p style=\"text-align: justify;\">InRAD is a free at the point-of-use registry that enables the collection of real-world data to further understanding about Alzheimer&#8217;s disease, and in the future, other dementias and to support clinical management. The registry is coordinated by the independent International Registry for Alzheimer&#8217;s Disease and Other Dementias Foundation, a health-related not-for-profit entity incorporated in the Netherlands. The registry platform will launch later in 2025, providing a secure, regionally compliant, Azure cloud-based registry platform and governance package.<\/p>\n","protected":false},"excerpt":{"rendered":"Korea&#8217;s Neurophet &amp; InRAD to establish global standards for Alzheimer&#8217;s disease and dementia data September 3, 2025 |&hellip;\n","protected":false},"author":2,"featured_media":40332,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[78],"tags":[291,5194,2594,868,18,135,19,30800,17,30799,30801,2428],"class_list":{"0":"post-40331","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-ai","9":"tag-alzheimers","10":"tag-data","11":"tag-dementia","12":"tag-eire","13":"tag-health","14":"tag-ie","15":"tag-inrad","16":"tag-ireland","17":"tag-neurophet","18":"tag-rd","19":"tag-south-korea"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/40331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=40331"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/40331\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/40332"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=40331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=40331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=40331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}